CN109091523A - 含金花葵的组合物 - Google Patents
含金花葵的组合物 Download PDFInfo
- Publication number
- CN109091523A CN109091523A CN201811161179.3A CN201811161179A CN109091523A CN 109091523 A CN109091523 A CN 109091523A CN 201811161179 A CN201811161179 A CN 201811161179A CN 109091523 A CN109091523 A CN 109091523A
- Authority
- CN
- China
- Prior art keywords
- golden flower
- composition
- seabuckthorn
- base fluid
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 24
- 239000012530 fluid Substances 0.000 claims abstract description 22
- 150000004676 glycans Chemical class 0.000 claims abstract description 22
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 20
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 18
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 17
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 17
- 239000003292 glue Substances 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 6
- 241000229143 Hippophae Species 0.000 claims description 47
- 239000000843 powder Substances 0.000 claims description 31
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 8
- 235000003935 Hippophae Nutrition 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000019605 sweet taste sensations Nutrition 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 10
- 150000002632 lipids Chemical class 0.000 abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 9
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 9
- 235000021014 blueberries Nutrition 0.000 description 9
- 208000026106 cerebrovascular disease Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 8
- 238000003672 processing method Methods 0.000 description 8
- 240000000851 Vaccinium corymbosum Species 0.000 description 7
- 229940100688 oral solution Drugs 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 241001075517 Abelmoschus Species 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 244000077233 Vaccinium uliginosum Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017454 sodium diacetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及医药保健领域,具体而言,涉及一种含金花葵的组合物。所述组合物以质量比为100:(20~30):(15~25)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;每20ml所述基液中还包括:几丁聚糖1g~3g、低聚木糖0.3g~0.7g以及高聚糖胶0.3g~0.7g。该产品能有效调节血脂,降低血压,降低血糖,具有全面调理心血管疾病的作用。
Description
技术领域
本发明涉及医药保健领域,具体而言,涉及一种含金花葵的组合物。
背景技术
心脑血管疾病就是心脏血管和脑血管的疾病统称。高血压、高血糖、高血脂被称为“富贵病”的“三高症”。60岁以上老年人中40%~45%患有高血压的同时还患有高血糖或高血脂,根据卫生部2007年统计数字显示,据国外的资料显示,50%左右的糖尿病人都合并有高血压、高血脂等多种老年疾病。心脑血管疾病具有“发病率高、致残率高、死亡率高、复发率高,并发症多”即“四高一多”的特点,严重威胁人类健康与生命。
心脑血管病变存在着共同的病理基础,如高血压、动脉硬化等,脑血管病变时,心脏本身可能已经存在隐性病变,冠状动脉粥样硬化,储备能力下降,代偿能力减弱;脑血管病变可累及丘脑下部和脑干的自主神经调节中枢,且可影响神经传导通路,对心脏的控制和调节发生紊乱,引起冠状动脉痉挛,造成心肌缺血。防治心脑血管疾病新药的研究一直是世界各国医药领域的重大课题,但现有的药物中至今一直未能在高效、速效、长效的结合上达到相应的统一,大部分人依靠西药长期控制,对身体伤害大。
有鉴于此,特提出本发明。
发明内容
本发明的目的在于提供一种含金花葵的组合物,所述组合物具有保健效果好,无明显的毒副反应等优点。
所述组合物以质量比为100:(20~30):(15~25)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1g~3g、低聚木糖0.3g~0.7g以及高聚糖胶0.3g~0.7g。
根据本发明的一方面,本发明还涉及如上所述的含金花葵的组合物在制备用于预防和/或治疗心脑血管疾病的药物或保健品中的应用。
与现有技术相比,本发明的有益效果为:
(1)效果好,纯天然配方,无明显的毒副反应;
(2)口感好,服用方便;
(3)能有效调节血脂,降低血压,降低血糖,具有全面调理心血管疾病的作用。
具体实施方式
本发明涉及一种含金花葵的组合物,所述组合物以质量比为100:(20~30):(15~25)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1g~3g、低聚木糖0.3g~0.7g以及高聚糖胶0.3g~0.7g。
可选的,如上所述的含金花葵的组合物,所述组合物以质量比为100:(22~28):(17~23)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1.5g~2.5g、低聚木糖0.4g~0.6g以及高聚糖胶0.4g~0.6g;
可选的,如上所述的含金花葵的组合物,所述组合物以质量比为100:(24~26:(19~21)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1.7g~2.2g、低聚木糖0.4g~0.6g以及高聚糖胶0.4g~0.6g。
金花葵又名菜芙蓉也称野芙蓉。金花葵花药食兼用,《本草纲目》已记载黄蜀葵的药用价值,能清热、凉血、解毒,其花无毒,具有清利湿热、消炎镇痛之功效,内服主治五淋、水肿,外用治疗汤水烫伤。果实、种子具有补脾健胃、生肌功效,治疗消化不良、不思饮食、跌打损伤等。《嘉佑本草》记载:黄蜀葵花主治小便淋漓及催生、治诸恶疮。现代医学研究表明,该花的总黄酮有镇痛、抗脑缺血和治疗口腔溃疡等作用。其所含全价蛋白质、高聚糖胶、膳食纤维、微量元素硒、锌、多种不皂化物等,具有显著调节人体内分泌、免疫力,增加人体抗力,改善心脑血管及微循环功能,增强机体抗氧化能力,抗心脑缺血、缺氧、抗炎、镇疼,抗疲劳、抗衰老、抗癌、防癌、降血脂功效。此外,其丰富的天然植物雌激素,对于延长女性青春期,减轻或避免中老年更年期综合症也有奇效。金花葵也含有丰富的金丝桃苷成分,而金丝桃苷具有明显的抗炎作用,有较强的止咳作用、同化作用,另外,还具有较强的抑制眼醛糖还原酶的作用。
蓝莓意为蓝色浆果,属杜鹃花科,越橘属植物。蓝莓果实中含有丰富的营养成分,具有防止脑神经老化、保护视力、强心、抗癌、软化血管、增强人机体免疫等功能,营养成分高。蓝莓中含有可帮助血管扩张的成分,进而降低血栓及心脏病危险。研究发现,每周吃5份以上蓝莓能降低心脏病危险。糖尿病患者吃蓝莓有助于调节血糖水平。每周吃5份蓝莓等低升糖指数水果,坚持两个月可显著改善血糖调节能力。本发明所采用的蓝莓提取物是蓝莓破碎磨汁后过滤所得。
沙棘又称沙棘果,具有很高的药用价值,沙棘果与沙棘叶中提取的总黄酮,具有增加冠状动脉血流量、增加心肌营养血流量、降低心肌耗氧量、抑制血小板聚集等作用,可以缓解心绞痛、增强心脏功能,提高在常压和低压下的耐缺氧能力,对垂体后叶引起的心肌缺血有明显的对抗作用。沙棘黄酮及其它活性物质具有降低高血压、软化血管,改善血液循环等作用,对缺血性脑血管病有防治和缓解作用,具有改善大脑供血供氧等作用。此外沙棘在防治冠状动脉粥样硬化等方面也有很好的效果。
几丁聚糖又称壳聚糖、甲壳素、脱乙酰甲壳素等。几丁聚糖是带正电荷的阳离子动物性食物纤维,又是自然界唯一存在的碱性多糖,因而决定了其具有重要的生理功能。血液中的总胆固醇和甘油三脂的含量过高,会诱发各种心血管病,直接威胁着人的生命。食物中脂类的消化需要胆汁酸作为乳化剂,正电性的几丁聚糖与负电荷的胆汁酸结合后排出体外,使脂肪不被乳化,从而阻碍脂肪的消化吸收。因胆固醇主要在肝脏中转化为胆汁酸减少,这就促进肝脏将胆固醇转化成胆汁酸,从而使血胆固醇降低。在体外特定比例的几丁聚糖可较好的络合胆汁酸,干扰机体对脂肪的吸收。
低聚木糖又称寡木糖,是一种优良的双歧杆菌增值因子。低聚木糖增殖双歧杆菌的功能是其他聚合糖的20倍,且对于肝道有双向调节作用,可使便秘或泻痢状况得到缓解。低聚木糖可改善肠内菌群,促进肠道蠕动,加剧食物通过肠道,抑制肠内有毒发酵产物生成,因而具有降低胆固醇的作用,低聚木糖有较好的降低血脂的功效。
高聚糖是单糖聚合度大于10的复合碳水化合物,许多葡萄糖分子连接成聚合物就形成了多糖。高聚糖胶指由高聚糖所形成的高聚糖。在一些实施方式中,若不特别说明,则高聚糖胶选自褐藻糖胶;褐藻糖胶具有抗肿瘤、抗凝血、降血脂等功能。
本发明通过合理调配金花葵、蓝莓和沙棘的比例和组成,不仅保健效果好,且口感好,易于被消费者所接受;既定配比的几丁聚糖、低聚木糖以及高聚糖胶配合后,能起到更佳的降血糖降血脂降血压功能。
可选的,如上所述的含金花葵的组合物,所述组合物中还包括甜味剂。
可选的,如上所述的含金花葵的组合物,所述甜味剂选自蜂蜜与麦芽糖。
可选的,如上所述的含金花葵的组合物,每20ml所述基液中,所述蜂蜜的含量为0.3g~0.7g,所述麦芽糖的含量为0.3g~0.7g。
可选的,如上所述的含金花葵的组合物,每20ml所述基液中,所述蜂蜜的含量为0.4g~0.6g,所述麦芽糖的含量为0.4g~0.6g。
可选的,如上所述的含金花葵的组合物,所述组合物中还包括膳食纤维。
膳食纤维可以以树胶、黏胶、果胶,谷物及一些高纤维含量丰富的蔬菜的形式添加。
在本发明中,膳食纤维的添加量以有效成分自纤维素,半纤维素和木质素计。可选的,每20ml所述基液中,,所述膳食纤维的含量为0.1~2g,还可以选择0.5g、1g、1.5g或1.7g。
可选的,如上所述的含金花葵的组合物,所述组合物中还包括食用防腐剂;
可选的,所述食用防腐剂选自苯甲酸及盐、脱氢乙酸钠、山梨酸钾、对羟基苯甲酸丙酯、丙酸钙、双乙酸钠、乳酸钠、纳他霉素、过氧化氢中的一种或多种。
可选的,如上所述的含金花葵的组合物,所述金花葵萃取液以及沙棘萃取液为使用水做溶剂萃取得到。
可选的,如上所述的含金花葵的组合物,所述金花葵萃取液或沙棘萃取液的制备方法包括:
按5~7g:20ml的固液比将金花葵粉或沙棘粉在常温常压下于水中浸泡4h~8h,过滤弃滤渣;
可选的,如上所述的含金花葵的组合物,所述金花葵萃取液的制备方法包括:
按6g:20ml的固液比将金花葵粉或沙棘粉在常温常压下于水中浸泡6h,过滤弃滤渣。
可选的,所述金花葵粉或沙棘粉的粒径≤25μm;
可选的,所述金花葵粉或沙棘粉通过以下方法处理得到,将金花葵的花蕾或沙棘果于35℃-70℃冷烘干后进行粉碎;
可选的,所述粉碎通过两次进行,第一次可粉碎至100~300目,第二次粉碎可以粉碎至500目以上;
第二次粉碎可采用超微粉碎机进行。
可选的,如上所述的含金花葵的组合物,所述组合物为口服液制剂。
口服液制剂使用方便,易于保存,是本发明的一种理想剂型。
根据本发明的一方面,本发明还涉及如上所述的含金花葵的组合物在制备用于预防和/或治疗心脑血管疾病、高血糖的药物或保健品中的应用。
可选的,所述心脑血管疾病选自高血压、高血脂、动脉硬化、冠心病。
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1
本实施例提供了一种金花葵口服液,其以蓝莓提取物、金花葵萃取液、沙棘萃取液为基液,每20ml添加几丁聚糖1g,低聚木糖0.7g以及高聚糖胶0.3g。
蓝莓提取物、金花葵萃取液、沙棘萃取液的质量比为100:20:25;
金花葵/沙棘的处理方法为:将金花葵的花蕾/沙棘果冷烘干,温度为35℃-70℃,然后粉碎至200目后,进行二次粉碎,可以粉碎至500目以上,获得金花葵粉。二次粉碎使用超微粉碎机。
金花葵萃取液的处理方法为:将金花葵粉/沙棘粉在常温常压下浸泡4h,其萃取比例为,每5g的金花葵粉用20ml水浸泡,然后过滤。
实施例2
本实施例提供了一种金花葵口服液,其以蓝莓提取物、金花葵萃取液、沙棘萃取液为基液,每20ml添加几丁聚糖3g,低聚木糖0.3g以及高聚糖胶0.7g。
蓝莓提取物、金花葵萃取液、沙棘萃取液的质量比为100:30:15;
金花葵/沙棘的处理方法为:将金花葵的花蕾/沙棘果冷烘干,温度为35℃-70℃,然后粉碎至200目后,进行二次粉碎,可以粉碎至500目以上,获得金花葵粉。二次粉碎使用超微粉碎机。
金花葵萃取液的处理方法为:将金花葵粉/沙棘粉在常温常压下浸泡8h,其萃取比例为,每5g的金花葵粉用20ml水浸泡,然后过滤。
实施例3
本实施例提供了一种金花葵口服液,其以蓝莓提取物、金花葵萃取液、沙棘萃取液为基液,每20ml添加几丁聚糖2.5g,低聚木糖0.4g,高聚糖胶0.5,麦芽糖0.6g,蜂蜜0.4g,膳食纤维0.5g。
蓝莓提取物、金花葵萃取液、沙棘萃取液的质量比为100:28:17;
金花葵/沙棘的处理方法为:将金花葵的花蕾/沙棘果冷烘干,温度为35℃-70℃,然后粉碎至200目后,进行二次粉碎,可以粉碎至500目以上,获得金花葵粉。二次粉碎使用超微粉碎机。
金花葵/沙棘萃取液的处理方法为:将金花葵粉/沙棘粉在常温常压下浸泡5h,其萃取比例为,每7g的金花葵粉用20ml水浸泡,然后过滤。
实施例4
本实施例提供了一种金花葵口服液,其以蓝莓提取物、沙棘萃取液和金花葵萃取液为基液,每20ml添加几丁聚糖2g,低聚木糖0.5g,高聚糖胶0.5,麦芽糖0.5g,蜂蜜0.5g,膳食纤维1g。
蓝莓提取物、金花葵萃取液、沙棘萃取液的质量比为100:25:20;
金花葵/沙棘的处理方法为:将金花葵的花蕾/沙棘果冷烘干,温度为35℃-70℃,然后粉碎至200目后,进行二次粉碎,可以粉碎至500目以上,获得金花葵粉。二次粉碎使用超微粉碎机。
金花葵萃取液的处理方法为:将金花葵粉/沙棘粉在常温常压下浸泡6h,其萃取比例为,每6g的金花葵粉用20ml水浸泡,然后过滤。
对比例1
同实施例4,区别仅在于将金花葵萃取液替换为等质量的蓝莓提取物和沙棘萃取液的混合物;
蓝莓提取物和沙棘萃取液的质量比为100:20。
对比例2
同实施例4,区别仅在于将低聚木糖和高聚糖胶替换为等质量的聚葡萄糖。
实验例1
检测实施例4所制备的口服液对自发性高血压大鼠(SHR)的降压效果,具体检测方法如下所示:
取重量为230~270g的自发性高血压Wistar大鼠(SHR)45只,随机分为3组,每组15只;
其中各组所饮用的口服液均经过1:2用水稀释,每日限量供应30mL,不额外提供水源。食品自由取用。连续喂食45日,检测喂食前以及喂食至第45日大鼠的血压。
具体检测结果如表1所示。根据表1所示实验数据可知,与对比例相比,本发明实施例4所制备的口服液能够显著降低自发性高血压大鼠的血压。
表1
实施例4 | 对比例1 | 对比例2 | |
喂食前(mmHg) | 185.85 | 181.72 | 187.31 |
第45日(mmHg) | 124.91 | 160.25* | 148.15* |
*p<0.05,vs实施例4(第45日)
实验例2
实验动物:采用ApoE-/-小鼠,使用南通特洛菲饲料科技有限公司生产的LAD0011饲料代替普通饲料进行高胆固醇模型建模。
ApoE-/-小鼠分为5组,每组十只。
空白对照组:食用TP 0600,0%胆固醇对照饲料,每日给饮用水10ml。
模型组:食用TP 0612,0.3%胆固醇模型饲料,每日给饮用水10ml。
实施例4组:食用TP 0612,0.3%胆固醇模型饲料,每日给实施例4制备得到的口服液10ml(与水按1:2稀释)。
对比例1组:食用TP 0612,0.3%胆固醇模型饲料,每日给对比例1制备得到的口服液10ml(与水按1:2稀释)。
对比例2组:食用TP 0612,0.3%胆固醇模型饲料,每日给对比例2制备得到的口服液10ml(与水按1:2稀释)。
饮食自由取用,饮水每日换新。
连续饲养45天后检测各组动物总胆固醇、甘油三酯、HDL2-ch及血清磷脂的值,取均值并进行比较,结果如表2所示。
表2
*p<0.05,vs模型组。
由上表可见,相比对比例1和2,实施例4可显著降低总胆固醇、甘油三酯的升高幅度,并能升高HDL2-ch与血清磷脂的水平,由于总胆固醇、甘油三酯水平过高会诱发动脉粥样硬化,而HDL2-ch及血清磷脂可帮助胆固醇的代谢,因而可降低高血脂的不良影响。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种含金花葵的组合物,其特征在于,所述组合物以质量比为100:(20~30):(15~25)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1g~3g、低聚木糖0.3g~0.7g以及高聚糖胶0.3g~0.7g。
2.根据权利要求1所述的含金花葵的组合物,其特征在于,所述组合物以质量比为100:(22~28):(17~23)的蓝莓提取物、金花葵萃取液、沙棘萃取液作为有效成分基液;
每20ml所述基液中还包括:
几丁聚糖1.5g~2.5g、低聚木糖0.4g~0.6g以及高聚糖胶0.4g~0.6g;
可选的,所述高聚糖胶为褐藻糖胶。
3.根据权利要求1所述的含金花葵的组合物,其特征在于,所述组合物中还包括甜味剂。
4.根据权利要求3所述的含金花葵的组合物,其特征在于,所述甜味剂选自蜂蜜与麦芽糖。
5.根据权利要求3所述的含金花葵的组合物,其特征在于,每20ml所述基液中,所述蜂蜜的含量为0.3g~0.7g,所述麦芽糖的含量为0.3g~0.7g。
6.根据权利要求1~5任一项所述的含金花葵的组合物,其特征在于,所述组合物中还包括膳食纤维。
7.根据权利要求1~5任一项所述的含金花葵的组合物,其特征在于,所述金花葵萃取液以及沙棘萃取液为使用水做溶剂萃取得到。
8.根据权利要求7所述的含金花葵的组合物,其特征在于,所述金花葵萃取液或沙棘萃取液的制备方法包括:
按5~7g:20ml的固液比将金花葵粉或沙棘粉在常温常压下于水中浸泡4h~8h,过滤弃滤渣;
可选的,所述金花葵粉或沙棘粉的粒径≤25μm;
可选的,所述金花葵粉或沙棘粉通过以下方法处理得到,将金花葵的花蕾或沙棘果于35℃-70℃冷烘干后进行粉碎。
9.根据权利要求1~5任一项所述的含金花葵的组合物,其特征在于,所述组合物为口服液制剂。
10.权利要求1~9任一项所述的含金花葵的组合物在制备用于预防和/或治疗心脑血管疾病、高血糖的药物或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811161179.3A CN109091523A (zh) | 2018-09-30 | 2018-09-30 | 含金花葵的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811161179.3A CN109091523A (zh) | 2018-09-30 | 2018-09-30 | 含金花葵的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109091523A true CN109091523A (zh) | 2018-12-28 |
Family
ID=64868031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811161179.3A Pending CN109091523A (zh) | 2018-09-30 | 2018-09-30 | 含金花葵的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109091523A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101273999A (zh) * | 2007-06-13 | 2008-10-01 | 淄博济世保健食品科技有限公司 | 金花葵产品及其用途 |
-
2018
- 2018-09-30 CN CN201811161179.3A patent/CN109091523A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101273999A (zh) * | 2007-06-13 | 2008-10-01 | 淄博济世保健食品科技有限公司 | 金花葵产品及其用途 |
Non-Patent Citations (3)
Title |
---|
赵秀玲: "蓝莓的成分与保健功能的研究进展", 《中国野生植物资源》 * |
闫涛,等: "沙棘的化学成分及生物功能的研究进展", 《吉林医药学院学报》 * |
雷波: "金花葵总黄酮对小鼠血脂影响的实验研究", 《宜春学院学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN103054113B (zh) | 一种具有降血糖功效的复合果蔬汁饮料 | |
CN101473953B (zh) | 净血排毒组合食品及其加工方法和应用 | |
KR101738912B1 (ko) | 비만억제 및 다이어트 조성물 | |
CN102511869B (zh) | 红枣生姜浓浆 | |
CN103005261B (zh) | 一种可抑制糖尿病患者餐后血糖升高的膳食补充剂 | |
CN101507494A (zh) | 高血脂高血压患者用的特殊膳食用食品 | |
CN104543834A (zh) | 一种具有降血糖功效的南瓜粉及其制备方法 | |
CN110447902A (zh) | 一种具有减肥功效的组合物 | |
JP6463504B2 (ja) | 発毛促進、脱毛緩和及び改善、血糖調節、胃腸障害の症状緩和及び改善用健康補助食品 | |
CN109329930A (zh) | 一种促进尿酸降低的组合物及其制备方法 | |
CN101766274B (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
CN111919934A (zh) | 一种用于降三高保护心血管的红花苏心茶及其制备方法 | |
CN111096416A (zh) | 用于减肥代餐的断食组合物及其制备方法 | |
KR20160032851A (ko) | 흰점박이 꽃무지를 주재료로 하는 환의 제조방법 | |
CN104814086A (zh) | 一种基于甘薯的功能性糕点及其制备方法 | |
CN105920198B (zh) | 一种具有补血功效的细胞破壁微粉及其制备方法 | |
CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
CN113796537B (zh) | 一种降糖组合物及其制作工艺 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
CN104305229B (zh) | 一种石斛膳食纤维食品及其加工方法 | |
CN109091523A (zh) | 含金花葵的组合物 | |
KR20180056199A (ko) | 모링가추출물을 함유한 다이어트용 껌의 제조방법 | |
KR20180033781A (ko) | 당뇨 예방 및 개선용 식품의 제조방법 | |
JP2009034017A (ja) | ダイエット食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181228 |